The development of new therapeutic agents is set to transform the treatment of hepatitis C over the coming years. For many patients, these treatments offer fewer and less severe side effects, a shorter treatment duration, a less complex regimen and dramatically improved rates of success compared to current interferon-based treatments. With the arrival of these new treatments, what role will patients play in managing their condition? And what types of support will they need to achieve the best results? To address these unknowns, we spoke with people living with hepatitis C, interviewed experts and reviewed the latest adherence research in this therapeutic area.